<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00758277</url>
  </required_header>
  <id_info>
    <org_study_id>Kep-F10.2.01</org_study_id>
    <nct_id>NCT00758277</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Levetiracetam in Prevention of Alcohol Relapse in Recently Detoxified Alcohol Dependent Patients</brief_title>
  <acronym>Keppra-2</acronym>
  <official_title>Efficacy and Safety of Levetiracetam in Prevention of Alcohol Relapse in Recently Detoxified Alcohol Dependent Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective randomized double blind controlled trial in prevention of relapse in recently&#xD;
      detoxified alcohol dependent patients with levetiracetam and placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Out-patients with alcohol dependence recently detoxified Primary goal size is the duration of&#xD;
      the Abstinenz up to the heavy relapse.&#xD;
&#xD;
      Secondary objective size are:&#xD;
&#xD;
        -  Frequency of Lapses&#xD;
&#xD;
        -  Time up to the first alcohol drinking&#xD;
&#xD;
        -  cumulative times of do not drink&#xD;
&#xD;
        -  Craving&#xD;
&#xD;
        -  Alcohol drinking quantity&#xD;
&#xD;
        -  Sleep quality&#xD;
&#xD;
        -  Tolerability/Bearableness of the study medication&#xD;
&#xD;
        -  Security&#xD;
&#xD;
        -  Drop Out rate&#xD;
&#xD;
        -  Side effects&#xD;
&#xD;
        -  Changes with the neuropsychological testing HAM-A, HAM-D, SF12, PSQI, VASC, OCDS, TLFB,&#xD;
           SCL-90.&#xD;
&#xD;
        -  Quality of life&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison alcohol free &quot;surviving &quot;(heavy alcohol relapse) between experimental therapy (Keppra®) and a group of placebos</measure>
    <time_frame>During and after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1 Time up to first drinking</measure>
    <time_frame>During treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 cumulative Time of do not drinking over the study duration</measure>
    <time_frame>during treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3 Frequency of Lapses</measure>
    <time_frame>during treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of the study medication</measure>
    <time_frame>during treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drop Out rate</measure>
    <time_frame>during treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>during treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes with the neuropsychological testing, HAM-A, HAM-D, SF12, VASC, OCDS, TLFB, SCL-90</measure>
    <time_frame>during treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>during treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">201</enrollment>
  <condition>Alcohol Dependence</condition>
  <condition>Alcoholic Relapse</condition>
  <arm_group>
    <arm_group_label>Levetiracetam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levetiracetam (Keppra)</intervention_name>
    <description>levetiracetam daily application 1500-2000 mg</description>
    <arm_group_label>Levetiracetam</arm_group_label>
    <other_name>KEPPRA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar Pill</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 and not older than 70 years&#xD;
&#xD;
          -  Good knowledge of the German language&#xD;
&#xD;
          -  The criteria of an alcohol dependence after DSM IV and ICD 10 fulfill&#xD;
&#xD;
          -  To the recruiting time alkoholabstinently living, i.e. after successful alcohol&#xD;
             decontamination, the patients must have understood the meaning and consequence of the&#xD;
             study and have delivered before beginning of study your written agreement to the&#xD;
             participation.&#xD;
&#xD;
          -  Negative drug screening regarding Benzodiazepines and Opiates.&#xD;
&#xD;
          -  With Females either o at least 1 year Menopause or after Sterilization or&#xD;
             contraceptive pill, mini pill, three-monthly syringe, Implanton, Vaginalring, hormone&#xD;
             plaster, hormone spiral at least 1 month before study inclusion or use of the double&#xD;
             barrier method with Spermiziddiaphragma plus condom use or renouncement of sexual&#xD;
             intercourse during the entire study duration and resolution a pregnancy to avoid with&#xD;
             negative β-HCG-test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Alcohol withdrawal syndrome beginning or existing&#xD;
&#xD;
          -  Simultaneous one ambulatory or stationary curing therapy, not however participation in&#xD;
             groups of self-helps&#xD;
&#xD;
          -  Specific ones behavior or deep-psychological single therapy or manual-led group&#xD;
             therapies parallel to the clinical study&#xD;
&#xD;
          -  Any further substance dependence except nicotine and/or Caffeine dependence A abuse&#xD;
             according to the criteria of DSM-IV and/or ICD-10 is not considered as exclusion&#xD;
             reason.&#xD;
&#xD;
          -  Idiopathic epilepsy, not however admitted alcohol withdrawal convulsions&#xD;
&#xD;
          -  Anamnesis of heavy cerebral traumas or other heavy neurological illnesses, not however&#xD;
             alcohol-associated neurological disturbances, e.g. Polyneuropathie&#xD;
&#xD;
          -  current CO-medication by means of medicines, which can affect significantly withdrawal&#xD;
             symptoms or Craving or promote the Abstinent( Benzodiazepines, Antiepileptics,&#xD;
             antipsychotics, Clonidin, antidepressives or Naltrexon (or substances with comparable&#xD;
             effect mechanism) or Acamprosat, Disulfiram, or further substances, which can affect&#xD;
             glutamaterge, dopaminerge, cholinergic, serotonerge or opiode system the GABAerge,&#xD;
&#xD;
          -  Contraindications or heavy side effects in relation to the study medication,&#xD;
             hypersensitivity opposite Pyrrolidonderivate&#xD;
&#xD;
          -  Pregnancy or quiet time or insufficient Contraception&#xD;
&#xD;
          -  Acute severe psychiatric disturbances in need of treatment of the axle I after DSM-IV&#xD;
&#xD;
          -  Acute Suizidalität, not convincingly arrangementable&#xD;
&#xD;
          -  Severe internal illnesses, e.g. Pancreatitis, pneumonia, cardiac infarct,&#xD;
             gastrointestinal bleedings etc.)&#xD;
&#xD;
          -  Severe kidney damage (starting from dekompensierter retention - stage 3 after that&#xD;
             national Kidney Foundation) or heavy liver damage (starting from Child A after Child&#xD;
             Pugh Score with living ore erring trousers) and/or creatinin Clearance of small&#xD;
             30ml/min&#xD;
&#xD;
          -  Simultaneous participation or within the last 4 weeks at another clinical study,&#xD;
             however does not exist an exclusion with previous participation in the decontamination&#xD;
             study with Keppra ® (Keppra 1).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Schaefer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Psychiarty, Charite Campus Mitte, Berlin, and Department of Psychiatry, Kliniken Essen-Mitte, Essen, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Nürnberg Nord</name>
      <address>
        <city>Nürnberg</city>
        <state>Bayern</state>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westfälisches Zentrum Bochum, Psychiatrie, Psychotherapie &amp; Psychosomatik, Klinik der Ruhr-Universität</name>
      <address>
        <city>Bochum</city>
        <state>NRW</state>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Psychiatrie und Psychotherapie</name>
      <address>
        <city>Bonn</city>
        <state>NRW</state>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Psychiatrie, Psychotherapie und Suchtmedizin Kliniken Essen - Mitte</name>
      <address>
        <city>Essen</city>
        <state>NRW</state>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für abhängiges Verhalten und Suchtmedizin, Rheinische Kliniken Essen, Kliniken der Universität Duisburg-Essen</name>
      <address>
        <city>Essen</city>
        <state>NRW</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für abhängiges Verhalten und Suchtmedizin, Rheinische Kliniken, Essen, Kliniken der Universität Duisburg - Essen</name>
      <address>
        <city>Essen</city>
        <state>NRW</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Psychiatrie und Psychotherapie der Martin-Luther-Universität Halle</name>
      <address>
        <city>Halle</city>
        <state>Sachsen-Anhalt</state>
        <zip>06097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Campus Mitte, Klinik für Psychiatrie und Psychotherapie</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PUK Charité im SHK</name>
      <address>
        <city>Berlin</city>
        <zip>10559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes, Wenckebach-Krankenhaus, Klinik für Psychiatrie und Psychotherapie, Gerontopsychiatrie/Psychosomatik</name>
      <address>
        <city>Berlin</city>
        <zip>12099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Psychiatrie und Psychotherapie, Jüdisches Krankenhaus Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Krebs M, Leopold K, Richter C, Kienast T, Hinzpeter A, Heinz A, Schaefer M. Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial. J Clin Psychopharmacol. 2006 Jun;26(3):347-9.</citation>
    <PMID>16702910</PMID>
  </reference>
  <verification_date>August 2009</verification_date>
  <study_first_submitted>September 23, 2008</study_first_submitted>
  <study_first_submitted_qc>September 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2008</study_first_posted>
  <last_update_submitted>June 22, 2011</last_update_submitted>
  <last_update_submitted_qc>June 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Martin Schaefer, MD</name_title>
    <organization>Charite University, Berlin, Germany</organization>
  </responsible_party>
  <keyword>prevention of alcohol relapse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levetiracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

